Supplementary file 1_Clinical effects of sodium–glucose cotransporter 2 inhibitors combine

A 2026 meta-analysis by Zhipeng Xu synthesizes results from 13 randomized controlled trials involving 22,238 patients with myocardial infarction. It compares the clinical effects and safety of adding sodium–glucose cotransporter 2 inhibitors to conventional therapy. The analysis reports outcomes including hospitalization for heart failure, major adverse cardiovascular events, and various safety metrics.

Use Cases

• Evaluating the efficacy of SGLT2 inhibitors on heart failure hospitalization risk based on the reported relative risk.
• Assessing the safety profile of combination therapy based on reported risks for renal dysfunction and glycemia-related adverse events.
• Comparing treatment effects on secondary outcomes like left ventricular ejection fraction and NT-proBNP levels.
• Conducting subgroup analyses based on diabetes status or timing of drug initiation as described in the methods.

Strengths

• Analysis is based on 13 randomized controlled trials, a robust study design for clinical evidence.
• Includes data from 22,238 patients, providing a substantial sample size for the meta-analysis.
• Reports specific statistical results, such as a relative risk of 0.76 for heart failure hospitalization.
• Examines multiple primary, secondary, and safety outcomes as detailed in the description.

Limitations

• The underlying dataset is a 16.6 KB DOCX file, suggesting it contains summary text/tables rather than raw patient-level data.
• Row count and column-level documentation for any potential tabular data are unknown.
• Freshness should be verified; the last update date is 2026-04-21, which is in the future relative to the current date.

Provenance

Source

Zhipeng Xu via figshare

Collection Method

Systematic review and meta-analysis of trials from PubMed, Web of Science, the Cochrane Library, and Embase.

Freshness

Last updated 2026-04-21 04:20:10